Clinical effectiveness and safety of generic versus branded amlodipine in hypertension:a single blind, prospective, randomized, crossover, non-inferiority trial.

IPGMER0 个研究点目标入组 28 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Subjects with Stage-I Hypertension of JNC-7 Classification i.e. Systolic Blood Pressure (SBP) of 140-159 mm of hg or Diastolic Blood Pressure(DBP) of 90-99 mm of hg who were not receiving any antihypertensive in the last 1 week before screening
•Subjects with Isolated systolic hypertension as per JNC 7 Classification i.e. Systolic Blood Pressure (SBP) of >= 140 mm of hg and Diastolic Blood Pressure (DBP) of < 90 mm of hg who were not receiving any antihypertensive medicines in the last 1 week prior to screening
•2.Age >= 18 but <= 70 years of either sex
•3.Subjects willing to give written informed consent and abide by all study related procedures

•(1)Subjects with blood pressure values out of range
•(2)Past history of hypersensitivity to Amlodipine
•(3)Female subjects who are pregnant or lactating
•(4)Any clinical condition that may be considered as unsuitable for study inclusion
•(5)Presence of any clinical condition that is contraindicated for Amlodipine use
•(6)History of pre-existing liver diseases or renal diseases

发起方

IPGMER